IMMURON LTD-SPON ADR (IMRN) Fundamental Analysis & Valuation

NASDAQ:IMRN • US45254U1016

0.88 USD
+0.1 (+12.82%)
At close: Mar 6, 2026
0.8401 USD
-0.04 (-4.53%)
After Hours: 3/6/2026, 8:26:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IMRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall IMRN gets a fundamental rating of 3 out of 10. We evaluated IMRN against 520 industry peers in the Biotechnology industry. The financial health of IMRN is average, but there are quite some concerns on its profitability. IMRN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. IMRN Profitability Analysis

1.1 Basic Checks

  • In the past year IMRN has reported negative net income.
  • In the past year IMRN has reported a negative cash flow from operations.
  • IMRN had negative earnings in each of the past 5 years.
  • In the past 5 years IMRN always reported negative operating cash flow.
IMRN Yearly Net Income VS EBIT VS OCF VS FCFIMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M

1.2 Ratios

  • IMRN has a Return On Assets (-51.49%) which is in line with its industry peers.
  • IMRN's Return On Equity of -64.64% is in line compared to the rest of the industry. IMRN outperforms 57.31% of its industry peers.
Industry RankSector Rank
ROA -51.49%
ROE -64.64%
ROIC N/A
ROA(3y)-37.77%
ROA(5y)-31.16%
ROE(3y)-46.18%
ROE(5y)-36.64%
ROIC(3y)N/A
ROIC(5y)N/A
IMRN Yearly ROA, ROE, ROICIMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • IMRN has a Gross Margin of 65.39%. This is in the better half of the industry: IMRN outperforms 80.00% of its industry peers.
  • In the last couple of years the Gross Margin of IMRN has declined.
  • The Profit Margin and Operating Margin are not available for IMRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.49%
GM growth 5Y-2.08%
IMRN Yearly Profit, Operating, Gross MarginsIMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. IMRN Health Analysis

2.1 Basic Checks

  • IMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IMRN has been increased compared to 1 year ago.
  • Compared to 5 years ago, IMRN has more shares outstanding
  • There is no outstanding debt for IMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMRN Yearly Shares OutstandingIMRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
IMRN Yearly Total Debt VS Total AssetsIMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

  • IMRN has an Altman-Z score of -8.63. This is a bad value and indicates that IMRN is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -8.63, IMRN is not doing good in the industry: 69.62% of the companies in the same industry are doing better.
  • IMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.63
ROIC/WACCN/A
WACC9.38%
IMRN Yearly LT Debt VS Equity VS FCFIMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

2.3 Liquidity

  • IMRN has a Current Ratio of 5.09. This indicates that IMRN is financially healthy and has no problem in meeting its short term obligations.
  • IMRN has a Current ratio of 5.09. This is comparable to the rest of the industry: IMRN outperforms 56.35% of its industry peers.
  • IMRN has a Quick Ratio of 4.19. This indicates that IMRN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of IMRN (4.19) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.09
Quick Ratio 4.19
IMRN Yearly Current Assets VS Current LiabilitesIMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. IMRN Growth Analysis

3.1 Past

  • IMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.66%, which is quite impressive.
  • The Revenue has grown by 48.63% in the past year. This is a very strong growth!
  • IMRN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.67% yearly.
EPS 1Y (TTM)25.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.07%
Revenue 1Y (TTM)48.63%
Revenue growth 3Y111.96%
Revenue growth 5Y23.67%
Sales Q2Q%29.26%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMRN Yearly Revenue VS EstimatesIMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
IMRN Yearly EPS VS EstimatesIMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. IMRN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IMRN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMRN Price Earnings VS Forward Price EarningsIMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMRN Per share dataIMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMRN Dividend Analysis

5.1 Amount

  • IMRN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMRN Fundamentals: All Metrics, Ratios and Statistics

IMMURON LTD-SPON ADR

NASDAQ:IMRN (3/6/2026, 8:26:42 PM)

After market: 0.8401 -0.04 (-4.53%)

0.88

+0.1 (+12.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner Change153.36%
Ins Owners7.03%
Ins Owner ChangeN/A
Market Cap7.11M
Revenue(TTM)7.29M
Net Income(TTM)-5.22M
Analysts0
Price TargetN/A
Short Float %0.23%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.39
P/FCF N/A
P/OCF N/A
P/B 1.25
P/tB 1.25
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0.64
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.49%
ROE -64.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.39%
FCFM N/A
ROA(3y)-37.77%
ROA(5y)-31.16%
ROE(3y)-46.18%
ROE(5y)-36.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.49%
GM growth 5Y-2.08%
F-Score2
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.09
Quick Ratio 4.19
Altman-Z -8.63
F-Score2
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.14%
Cap/Sales(5y)1.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.07%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)48.63%
Revenue growth 3Y111.96%
Revenue growth 5Y23.67%
Sales Q2Q%29.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.37%
OCF growth 3YN/A
OCF growth 5YN/A

IMMURON LTD-SPON ADR / IMRN FAQ

What is the fundamental rating for IMRN stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMRN.


What is the valuation status for IMRN stock?

ChartMill assigns a valuation rating of 0 / 10 to IMMURON LTD-SPON ADR (IMRN). This can be considered as Overvalued.


Can you provide the profitability details for IMMURON LTD-SPON ADR?

IMMURON LTD-SPON ADR (IMRN) has a profitability rating of 1 / 10.


Can you provide the financial health for IMRN stock?

The financial health rating of IMMURON LTD-SPON ADR (IMRN) is 6 / 10.